1.

Selected phase III trials addressing the role of chemotherapy concomitant and adjunctive to RT

Author (ref.)	No. of eligible patients	FIGO stage	Histology	Study arms	Chemotherapy regimen	Survival
FIGO, International Federation of Gynecology and Obstetrics; 1, IB2 and IIA (≥5 cm), IIB–IVA or histologically confirmed pelvic lymph node involvement; 2, I, II with histologically confirmed pelvic/paraaortic lymph node involvement; SCC, squamous cell carcinoma; ADC, adenocarcinoma; ADS, adenosquamous carcinoma; RT, radiation therapy; CCRT, concomitant chemoradiotherapy; S, surgery; ACT, adjuvant chemotherapy; CDDP, cisplatin; 5-FU, 5-fluorouracil; HU, hydroxyurea; EPI, epirubicin; *, calculated from survival curves; MMC, mitomycin C; GEM, gemcitabine; OS, overall survival; DFS, disease-free survival; PFS, progression-free survival; NS, not significant.
Keys et al. (1999) (4)	369	IB2	SCC, ADC, ADS	RT CCRT (both arms followed by S)	CDDP	4-year OS 74% vs. 83% (P=0.008)
Morris et al. (1999) (5,6)	403	IB2–IVA	SCC, ADC, ADS	RT CCRT	CDDP+5-FU	8-year OS 41% vs. 67% (P<0.0001)
Rose et al. (1999) (7,8)	526	IIB–IVA	SCC, ADC, ADS	CCRT CCRT CCRT	HU CDDP CDDP+5-FU+HU	2-year OS 50% vs. 66% vs. 67% (P=0.002) (10-year OS 34% vs. 53% vs. 53%)
Whitney et al. (1999) (9)	368	IIB-IVA	SCC, ADC, ADS	CCRT CCRT	HU CDDP+5-FU	5-year OS 43% vs. 55% (P=0.018)
Wong et al. (1999) (10)	220	I, II, III “bulky”	SCC	CCRT CCRT+ACT	EPI during RT and as ACT	5-year OS 68% vs. 79% (P=0.04)*
Pearsey et al. (2002) (11)	253	IB–IVA1	SCC	RT CCRT	CDDP	5-year OS 62% vs. 58% (NS)
Lorvidhaya et al. (2003) (12)	926	IIB–IVA	SCC, ADC, ADS	RT RT+ACT CCRT CCRT+ACT	MMC+oral 5-FU during RT ACT: oral 5-FU	5-year DFS 48.2% vs. 54.1% vs. 64.5% vs. 59.7%
Duenas-Gonzalez et al. (2011) (13)	515	IIB–IVA	SCC, ADC, ADS, poorly differentiated carcinoma	CCRT CCRT as above + ACT	CDDP+GEM during RT ACT: CDDP+GEM	3-year PFS 65% vs. 74% (P=0.029)
Wang et al. (2015) (14)	74	I, II2, III, IVA	SCC	CCRT CCRT	CDDP CDDP+GEM	3-year OS 74.1% vs. 85.9% (NS)